- ConvaTec’s full-year revenue for 2024 was exactly $2.29 billion, meeting market estimates.
- Advanced Wound Care revenue came in slightly below expectations at $742.7 million compared to an estimate of $749.1 million.
- Ostomy Care revenue was reported at $634.0 million, slightly under the $637.7 million estimate.
- Continence & Critical Care revenue exceeded expectations with $501.4 million compared to the estimated $496.5 million.
- Infusion Care revenue surpassed predictions, reaching $410.9 million against an estimate of $402.2 million.
- Adjusted Earnings Before Interest and Taxes (Ebit) was $485.3 million, beating the estimate of $481.7 million.
- Earnings Before Interest and Taxes (Ebit) was $324.9 million, falling short of the $339.1 million estimation.
- The Adjusted Earnings Per Share (EPS) was 15.2 cents, slightly higher than the projected 15.1 cents.
- Adjusted EBITDA came in at $590.5 million, surpassing the $580 million estimate.
- A final dividend of 4.594 cents per share was announced.
- The company expects strong strategic progress in 2025 due to an innovative product pipeline and improvements in productivity and simplification.
- Analyst recommendations include 17 buys, 2 holds, and 1 sell.
A look at Convatec Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Convatec, a manufacturer of medical and surgical equipment, has a promising long-term outlook based on the Smartkarma Smart Scores. With a strong score in Growth and Momentum, the company shows potential for expansion and positive market performance. This indicates Convatec‘s ability to innovate and adapt to changing industry trends, positioning it well for future growth opportunities. While the Value and Resilience scores are moderate, the higher scores in Growth and Momentum point towards a positive trajectory for Convatec in the long term.
Known for its wide range of medical products like urine meters, dressings, and negative pressure wound systems, Convatec has a solid foundation for sustained growth and market presence. The company’s above-average score in Dividend signifies a commitment to rewarding investors, adding to its attractiveness for those seeking stable returns alongside potential growth. Despite some average scores in certain areas, Convatec‘s overall Smart Scores suggest a promising outlook, backed by its global market reach and diverse product offerings.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
